Inhibition of labile aggregation-stimulating substance (LASS) and platelet aggregation in diabetes mellitus.
Irreversible second-phase aggregation of platelets in diabetic patients is prevented in vitro by 5, 8, 11, 14-eicosatetraynoic acid (TYA), a competitive inhibitor of the labile aggregation-stimulating substance (LASS) which is formed from arachidonic acid. Thus, inhibition of prostaglandin synthesis inhibits platelet aggregation in diabetic subjects. These findings indicate that platelets from diabetics are subject to control by intracellular mechanisms operative in the regulation of platelet function in normal individuals.
D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D001792:Blood Platelets / Q000503:physiopathology; D003094:Collagen / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000097:blood* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D005165:Factor V / Q000037:antagonists & inhibitors*; D005231:Fatty Acids, Unsaturated / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D006801:Humans; D010545:Peroxides / Q000037:antagonists & inhibitors; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000378:metabolism
D005231:Fatty Acids, Unsaturated; D010545:Peroxides; D011453:Prostaglandins; D015117:5,8,11,14-Eicosatetraynoic Acid; D000244:Adenosine Diphosphate; D005165:Factor V; D003094:Collagen; D004837:Epinephrine